Kidney cancer is the most common cancer in the world around 63,990 new cases are estimated to be in 2017. Among the primary kidney cancer, renal parenchymal cancer is the most common estimating around 80-90% and it is the most complex to treat. The chances of developing cancer is about 1 in 63 in lifetime, with higher risk in men than women. There is rise in the incidences of renal cell carcinoma in recent decade, due to unhealthy lifestyle such as smoking, obesity and decline in physical activity. Thus, with increase in aged population and growth in incidences of kidney cancer and drugs in pipeline for approval would drive the growth of kidney cancer drug market.
The report titled Kidney Cancer/Renal Cell Carcinoma Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030; offers strategic insights into the overall kidney cancer drugs market along with the market size and estimates for the duration 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drug and different geographies. Further cross-sectional presented in terms of drug and constituent region/country level markets is also included in this section.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global kidney cancer drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global kidney cancer/renal cell cancer drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global kidney cancer/renal cell carcinoma drugs market. In-depth competitive environment analysis and historical (2020) market size data are also provided in the report.
Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ag, Genentech, Inc., GlaxoSmithKline Plc, Novartis AG, Onyx, Pfizer, Inc. and others.
Renal cell carcinoma is the most common type of cancer observed in developed countries. Surgical treatment do not suffice at times and need other additional treatments. Most promising treatment is target therapies that are commonly used for of kidney cancer. Sutent, Nexavar, Votrient are commonly used drugs for renal cell carcinoma treatment. Sutent occupies the largest share, thus dominating the kidney cancer drugs market. It is most commonly prescribed first line treatment drug for renal cell carcinoma. Votrient is anticipated to be the fast growing market in the forecast period. With patent expiry of branded drugs, entry of generics would affect the kidney cancer drugs market negatively. However, novel drugs in phase 2 and 3 of clinical trials would further propel the growth of kidney cancer drugs market.
In 2021, North America occupies the major share of kidney cancer drugs market followed by Europe. North America and Europe have the highest incidences of kidney cancer and lowest is found in Africa and Asia. It is observed that kidney cancer is more prevalent in developed region around 59%. In U.S. around 65,000 new cases are diagnosed each year and 13,500 deaths occur due to renal cell carcinoma annually. It is the seventh most common cancer in men and the ninth most common in women. Rise in incidences of kidney cancer, well established healthcare infrastructure and favorable reimbursement policies are some of the key reasons for growth of kidney cancer/renal cell carcinoma drugs market in North America. Asia Pacific is the fastest growing kidney cancer/renal cell carcinoma drugs market. Rising geriatric population, improvement in overall healthcare infrastructure, increase in patient awareness availability of generics and improved diagnostic technology are the key reason for the growth of lucrative Asia Pacific market.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
The report titled Kidney Cancer/Renal Cell Carcinoma Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030; offers strategic insights into the overall kidney cancer drugs market along with the market size and estimates for the duration 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drug and different geographies. Further cross-sectional presented in terms of drug and constituent region/country level markets is also included in this section.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global kidney cancer drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global kidney cancer/renal cell cancer drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global kidney cancer/renal cell carcinoma drugs market. In-depth competitive environment analysis and historical (2020) market size data are also provided in the report.
Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ag, Genentech, Inc., GlaxoSmithKline Plc, Novartis AG, Onyx, Pfizer, Inc. and others.
Renal cell carcinoma is the most common type of cancer observed in developed countries. Surgical treatment do not suffice at times and need other additional treatments. Most promising treatment is target therapies that are commonly used for of kidney cancer. Sutent, Nexavar, Votrient are commonly used drugs for renal cell carcinoma treatment. Sutent occupies the largest share, thus dominating the kidney cancer drugs market. It is most commonly prescribed first line treatment drug for renal cell carcinoma. Votrient is anticipated to be the fast growing market in the forecast period. With patent expiry of branded drugs, entry of generics would affect the kidney cancer drugs market negatively. However, novel drugs in phase 2 and 3 of clinical trials would further propel the growth of kidney cancer drugs market.
In 2021, North America occupies the major share of kidney cancer drugs market followed by Europe. North America and Europe have the highest incidences of kidney cancer and lowest is found in Africa and Asia. It is observed that kidney cancer is more prevalent in developed region around 59%. In U.S. around 65,000 new cases are diagnosed each year and 13,500 deaths occur due to renal cell carcinoma annually. It is the seventh most common cancer in men and the ninth most common in women. Rise in incidences of kidney cancer, well established healthcare infrastructure and favorable reimbursement policies are some of the key reasons for growth of kidney cancer/renal cell carcinoma drugs market in North America. Asia Pacific is the fastest growing kidney cancer/renal cell carcinoma drugs market. Rising geriatric population, improvement in overall healthcare infrastructure, increase in patient awareness availability of generics and improved diagnostic technology are the key reason for the growth of lucrative Asia Pacific market.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs market and their expected impact during the forecast period.
Market Segmentation
Type
- Afinitor (Everolimus)
- Avastin (Bevacizumab)
- Cabomety (Cabozantinib)
- Inlyta (Axitinib)
- Nexavar (Sorafenib)
- Proleukin (Aldesleukin)
- Torisel (Temsirolimus)
- Sutent (Sunitinib)
- Votrient (Pazopanib)
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs market?
- Which is the largest regional market for Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market
2.2. Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, By Type, 2021 (US$ Million)
2.3. Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market Vendors
3.2. Strategies Adopted by Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Afinitor (Everolimus)
5.3.2. Avastin (Bevacizumab)
5.3.3. Cabomety (Cabozantinib)
5.3.4. Inlyta (Axitinib)
5.3.5. Nexavar (Sorafenib)
5.3.6. Proleukin (Aldesleukin)
5.3.7. Torisel (Temsirolimus)
5.3.8. Sutent (Sunitinib)
5.3.9. Votrient (Pazopanib)
6. North America Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
6.3.Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
7. UK and European Union Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
7.3.Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
8. Asia Pacific Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
8.3.Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
9. Latin America Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
9.3.Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
10. Middle East and Africa Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
10.3.Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: By Type, 2020-2030, USD (Million)
11. Company Profile
11.1. Active Biotech Ab
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Amgen
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Bayer AG
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Cipla Limited
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. F. Hoffmann-La Roche Ag
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Genentech, Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Glaxosmithkline Plc
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Novartis Ag
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Onyx
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Pfizer, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Other Notable Players
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
List of Figures
Figure 1 Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market: Quality Assurance
Figure 5 Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, By Type, 2021
Figure 6 Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, 2021
Figure 8 Market Positioning of Key Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market Players, 2021
Figure 9 Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market, By Type, 2021 Vs 2030, %
Figure 11 U.S. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 12 Canada Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 14 UK Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 15 Germany Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 16 Spain Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 17 Italy Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 18 France Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 20 China Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 21 Japan Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 22 India Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 23 Australia Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 24 South Korea Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 26 Brazil Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 27 Mexico Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 29 GCC Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 30 Africa Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 2 North America Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 3 U.S. Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 4 Canada Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 5 Rest of North America Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 6 UK and European Union Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 7 UK Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 8 Germany Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 9 Spain Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 10 Italy Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 11 France Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 12 Rest of Europe Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 13 Asia Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 14 China Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 15 Japan Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 16 India Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 17 Australia Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 18 South Korea Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 19 Latin America Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 20 Brazil Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 21 Mexico Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 22 Rest of Latin America Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 23 Middle East and Africa Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 24 GCC Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 25 Africa Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type, 2020-2030, USD (Million)
Companies Mentioned
- Active Biotech Ab
- Amgen
- Bayer AG
- Cipla Limited
- F. Hoffmann-La Roche Ag
- Genentech Inc.
- GlaxoSmithKline Plc
- Novartis AG
- Onyx
- Pfizer Inc.
